SciSparc Announces Positive Topline Results For Proprietary Pain Management Compound In Pre-Clinical Study
Ryan Allway August 2nd, 2021 Study Results Indicate SCI-160 Has A Significant Analgesic Effect on Acute and Chronic Pain TEL AVIV, Israel, Aug. 2, 2021 /PRNewswire/ — SciSparc Ltd. (OTCQB: SPRCY) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160... Read more
SciSparc Announces Updates Regarding its Phase IIb Study in Tourette Syndrome
Ryan Allway July 26th, 2021 SciSparc intends to evaluate the efficacy, safety and tolerability of its Proprietary Cannabinoid-Based Treatment- SCI-110 TEL AVIV, Israel, July 26, 2021 /PRNewswire/ — SciSparc Ltd. (OTCQB: SPRCY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced a number of updates regarding... Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )